INS and type 1 diabetes mellitus: OX40 agonistic antibody (OX86) treatment induces CD4+CD25+Foxp3+ Tregs and CD4+Foxp3- T cells expressing the latency-associated peptide and reduces T1D incidence of NOD mice, which play a synergistic role with insulin B9:23.